These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 12853420)

  • 1. Group II metabotropic glutamate receptors regulate the vulnerability to hypoxic brain damage.
    Poli A; Beraudi A; Villani L; Storto M; Battaglia G; Di Giorgi Gerevini V; Cappuccio I; Caricasole A; D'Onofrio M; Nicoletti F
    J Neurosci; 2003 Jul; 23(14):6023-9. PubMed ID: 12853420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological activation of mGlu2/3 metabotropic glutamate receptors protects retinal neurons against anoxic damage in the goldfish Carassius auratus.
    Beraudi A; Bruno V; Battaglia G; Biagioni F; Rampello L; Nicoletti F; Poli A
    Exp Eye Res; 2007 Mar; 84(3):544-52. PubMed ID: 17196590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predominant expression of group-II metabotropic glutamate receptors in the goldfish brain.
    Poli A; Lucchi R; Storto M; De Paolis P; Notari S; Nicoletti F; Casabona G
    Brain Res; 1999 Jul; 834(1-2):142-5. PubMed ID: 10407103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis.
    Scaccianoce S; Matrisciano F; Del Bianco P; Caricasole A; Di Giorgi Gerevini V; Cappuccio I; Melchiorri D; Battaglia G; Nicoletti F
    Neuropharmacology; 2003 Apr; 44(5):555-61. PubMed ID: 12668041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors.
    Kingston AE; Ornstein PL; Wright RA; Johnson BG; Mayne NG; Burnett JP; Belagaje R; Wu S; Schoepp DD
    Neuropharmacology; 1998; 37(1):1-12. PubMed ID: 9680254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo modulation of extracellular hippocampal glutamate and GABA levels and limbic seizures by group I and II metabotropic glutamate receptor ligands.
    Smolders I; Lindekens H; Clinckers R; Meurs A; O'Neill MJ; Lodge D; Ebinger G; Michotte Y
    J Neurochem; 2004 Mar; 88(5):1068-77. PubMed ID: 15009663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabotropic glutamate (mGLU)2/3 receptor antagonist LY341495 [2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9-yl)propanoic acid] stimulates waking and fast electroencephalogram power and blocks the effects of the mGLU2/3 receptor agonist ly379268 [(-)-2-oxa-4-aminobicyclo[3.1.0]hexane-4,6-dicarboxylate] in rats.
    Feinberg I; Schoepp DD; Hsieh KC; Darchia N; Campbell IG
    J Pharmacol Exp Ther; 2005 Feb; 312(2):826-33. PubMed ID: 15383637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0] hexane-2,6-dicarboxylic acid (LY354740): identification of two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors.
    Monn JA; Valli MJ; Massey SM; Hansen MM; Kress TJ; Wepsiec JP; Harkness AR; Grutsch JL; Wright RA; Johnson BG; Andis SL; Kingston A; Tomlinson R; Lewis R; Griffey KR; Tizzano JP; Schoepp DD
    J Med Chem; 1999 Mar; 42(6):1027-40. PubMed ID: 10090786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The preferential mGlu2/3 receptor antagonist, LY341495, reduces the frequency of spike-wave discharges in the WAG/Rij rat model of absence epilepsy.
    Ngomba RT; Biagioni F; Casciato S; Willems-van Bree E; Battaglia G; Bruno V; Nicoletti F; van Luijtelaar EL
    Neuropharmacology; 2005; 49 Suppl 1():89-103. PubMed ID: 16043198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
    Sanger H; Hanna L; Colvin EM; Grubisha O; Ursu D; Heinz BA; Findlay JD; Vivier RG; Sher E; Lodge D; Monn JA; Broad LM
    Neuropharmacology; 2013 Mar; 66():264-73. PubMed ID: 22659090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
    Rorick-Kehn LM; Johnson BG; Burkey JL; Wright RA; Calligaro DO; Marek GJ; Nisenbaum ES; Catlow JT; Kingston AE; Giera DD; Herin MF; Monn JA; McKinzie DL; Schoepp DD
    J Pharmacol Exp Ther; 2007 Apr; 321(1):308-17. PubMed ID: 17204749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Group II metabotropic glutamate receptor activation by agonist LY379268 treatment increases the expression of brain derived neurotrophic factor in the mouse brain.
    Di Liberto V; Bonomo A; Frinchi M; Belluardo N; Mudò G
    Neuroscience; 2010 Feb; 165(3):863-73. PubMed ID: 19909793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice.
    Molinaro G; Traficante A; Riozzi B; Di Menna L; Curto M; Pallottino S; Nicoletti F; Bruno V; Battaglia G
    Mol Pharmacol; 2009 Aug; 76(2):379-87. PubMed ID: 19439499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
    Cartmell J; Monn JA; Schoepp DD
    J Pharmacol Exp Ther; 1999 Oct; 291(1):161-70. PubMed ID: 10490900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [3H]-LY341495 as a novel antagonist radioligand for group II metabotropic glutamate (mGlu) receptors: characterization of binding to membranes of mGlu receptor subtype expressing cells.
    Johnson BG; Wright RA; Arnold MB; Wheeler WJ; Ornstein PL; Schoepp DD
    Neuropharmacology; 1999 Oct; 38(10):1519-29. PubMed ID: 10530814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
    Galici R; Echemendia NG; Rodriguez AL; Conn PJ
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective blockade of mGlu5 metabotropic glutamate receptors protects rat hepatocytes against hypoxic damage.
    Storto M; de Grazia U; Knöpfel T; Canonico PL; Copani A; Richelmi P; Nicoletti F; Vairetti M
    Hepatology; 2000 Mar; 31(3):649-55. PubMed ID: 10706555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells.
    D'Onofrio M; Arcella A; Bruno V; Ngomba RT; Battaglia G; Lombari V; Ragona G; Calogero A; Nicoletti F
    J Neurochem; 2003 Mar; 84(6):1288-95. PubMed ID: 12614329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The group I metabotropic glutamate receptor antagonist S-4-CPG modulates the locomotor response produced by the activation of D1-like, but not D2-like, dopamine receptors in the rat nucleus accumbens.
    David HN; Abraini JH
    Eur J Neurosci; 2001 Jun; 13(11):2157-64. PubMed ID: 11422457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabotropic glutamate receptor subtypes differentially influence neuronal recovery from in vitro hypoxia/hypoglycemia in rat hippocampal slices.
    Opitz T; Richter P; Carter AJ; Kozikowski AP; Shinozaki H; Reymann KG
    Neuroscience; 1995 Oct; 68(4):989-1001. PubMed ID: 8545005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.